With the human DNA sequence nearing completion, the search for complex disease genes is gaining momentum, as is the debate over gene-finding strategies. This overview contrasts two pivotal methods: linkage analysis and association mapping. Linkage analysis has been used successfully to identify the genes underlying rare mendelian disorders. It has also played a role in attempts to map genes for common non-mendelian (also known as 'complex' or 'multifactorial') diseases such as psychiatric disorders. However, despite extensive efforts progress has been slow, marred by inconsistent or ambiguous results. Uncertainties about the utility of the linkage approach for complex genetic traits has spurred interest in association studies with candidate genes, as an alternate strategy. Recently, with the advent of new molecular tools, in particular high-density, single-nucleotide polymorphisms (SNPs) maps, it has been argued that, while linkage analysis may retain some role, genome-wide association studies with SNPs offer a superior strategy for unraveling genetic complexity. In this paper I review these issues, stressing the pros and cons of the various strategies. I propose that: (1) the uncertainties in association studies may have been underestimated; (2) neither method is sufficient or optimal; and (3) a joint linkage and association approach, together with genomic, statistical and computational advances, may have greater promise for understanding the genetic underpinnings of complex disorders in the new millennium. Molecular Psychiatry (2001) 6, 143-149.
cally linked. An array of family configurations can be tested, such as multiplex extended pedigrees and nuclear families with affected sib-pairs. Association studies examine the co-occurrence of a marker and disease at the population level, usually by comparing marker frequencies in unrelated cases and controls (a case-control design). Simplex families with an affected child (a 'trio' design involving the affected child and the parents) and sib-pair families can also be used in association studies. Disease-marker association can be explained by two genetic mechanisms: pure association and linkage disequilibrium. In pure association the marker allele itself is involved in disease risk, namely, it might implicate a candidate gene. Linkage disequilibrium stems from a marker locus sufficiently close to the disease locus that allele frequencies at the two loci have not reached equilibrium in the population. Linkage and association studies can employ both 'reverse-genetics' (testing random, anonymous DNA markers) and 'forward-genetics' (using candidategene polymorphisms with presumed functional significance for the disease), though 'forward-genetics' is the mainstay of association mapping.
Traditionally, linkage analysis has been the primary method for mapping mendelian disorders. It has also played a prominent role in attempts to map complex disorders, on the assumption that mendelian subtypes with genes of relatively large effect can be identified.
Recently, however, association studies of complex disease have become conspicuous. For example, in psychiatric genetics there are numerous accounts of association between candidate genes (genes encoding products with neurobiological function such as neurotransmitter receptors and enzymes) and behavioral traits ranging from normal personality variants to psychopathological states. A recent paper in a highranking journal underscores this trend by suggesting that, while linkage analysis may continue to have some role, association studies (albeit more systematic than the traditional design) offer a superior strategy with a greater yield. 1 However, the resurgent association approach is not a panacea. Also, because the potential contribution of linkage mapping is far from exhausted (as also evidenced by substantial public funding for ongoing large-scale genome-wide linkage studies, both in the US and Europe), it would be instructive to revisit these issues. (The hallmarks of linkage and association studies are noted in Table 1 and are explicated below.)
Association
How can one account for the increased popularity of association studies? There are two main reasons for this trend. First, the inconsistent results of linkage studies-partly attributed to complex inheritance, leading to reduced statistical power and difficulty in discerning a true-positive from a false-positive-have diminished enthusiasm for the linkage approach. Second, whereas linkage studies require costly and involved procedures for the collection of family data (especially multiplex extended pedigrees), traditional case-control association studies involving a small number of candidate genes are more economical and easier to perform.
It is apparent, however, that the spectre of conflicting results is at least as pronounced in association studies, and that 'significant' disease-marker associations are more likely than not to be spurious. As discussed, [2] [3] [4] [5] [6] [7] [8] the main culprits are the substantial odds against plucking the 'right' candidate gene for association mapping, and artifacts arising from population stratification due to ethnic variation. Whereas sample stratification can be rectified by adherence to ethnic homogeneity and family-based controls (as opposed to controls obtained from the general population), the infinitesimal odds of selecting a likely candidate gene are certain to defeat most attempts at a compelling association finding. For example, in the absence of clear knowledge of biological substrates for psychiatric disorders and other behavioral traits, all genes expressed in the human brain (estimated at tens of thousands) are potential candidates. To curb false-positives, the selection of one or several such genes for association analysis, on the basis of a 'favored' neurobiological hypothesis (the usual practice), would require P values much more stringent (by orders of magnitude) than those commonly reported for 'significant' results, even with samples considerably larger than what is deemed 'realistic'. 2, 4 With the advent of new molecular tools, in particular high-density, single-nucleotide polymorphisms (SNPs) maps, 9 the conventional candidate-gene association design can be supplanted by more systematic strategies, such as genome-wide large-scale linkage disequilibrium mapping using tens of thousands of candidate-SNPs (coding or promoter variants with potential functional significance). 10 It has been proposed that, using this approach, case-control association studies provide adequate power to detect genes with genotype relative risks as low as 1.5 and allele frequencies as high as 0.70 (ie, parameters often associated with complex genetic diseases), even using a stringent significance level (P = 5 × 10 −8 ) to curtail false-positives. 1, 10 However, the prospects of this approach are tempered by important caveats. First, there is a debate about the most efficient approach to SNP mapping. For example, some researchers have suggested that non-coding or evenly spaced SNPs should also be used, and that as many as 500 000 SNPs may be needed, increasing the number of markers several fold. 11, 12 Although DNA pooling 13 can expedite this effort, the mapping effort required is still considerable and there are uncertainties, such as the accurate interpretation of SNP allele frequencies obtained from pooled DNA amplification. 13 Second, even at high-density SNP mapping, many disease genes may be missed because, unlike linkage analysis, a negative linkage disequilibrium result (especially with non-coding SNPs) does not rule out a significant gene effect in a particular genomic region. 1 Third, new data suggest that the extent of linkage disequilibrium is highly variable across the genome, 14 and that a whole-genome linkage disequilibrium map is needed, to enhance the efficiency and accuracy of these studies. 12 Fourth, there are statistical issues that may hamper the interpretation of SNP association studies, such as appropriate P-value criteria to weed out false-positives given the vast number of test results, and the possibility that there may never be enough power to detect with confidence modest gene effects in the event of substantial allelic heterogeneity. 15, 16 Given these uncertainties, there is no assurance of greater power for association analysis with increased sample size, whereas the power of linkage mapping is bound to increase. 16 A further confounding factor is population heterogeneity. It has been shown that, unless a common ancestor is fairly recent, there may not be enough power to detect gene effects, even with very large population samples. 17 Other complications summarized elsewhere 18 include high recombination rates that can disrupt the correlation between SNPs and disease-related variants, and the presence of multiple mutations (per gene) that predispose an individual to disease, which may hinder the detection of gene effects in an SNP analysis.
Linkage
What, then, is the relative merit of linkage analysis? Can linkage mapping be truly relegated backstage?
The 'anti-linkage, pro-association' stance can be summed up as follows: (1) Linkage analysis is best suited for mendelian disorders. Mendelian subforms of complex disease are rare, can easily be missed and, in any event, may not be relevant for the majority of cases.
(2) Most of the genetic variance in complex disorders can be accounted for by genes of modest effect, which are not amenable to the linkage approach but are detectable through association analysis. (3) To the extent that some genes of small effect can be uncovered by linkage analysis, it would be necessary to assemble samples of 'unrealistic' size, to achieve adequate statistical power.
10 (4) The diverse and conflicting results in linkage studies of complex disorders attest to the limited utility of this approach. There are, however, counterarguments:
Mendelian subforms of complex disease
There are several success stories, such as Alzheimer's disease (beta-amyloid precursor protein and presenilin-1 and -2), breast cancer (BRCA-1 and -2), colon cancer (familial adenomatous polyposis and hereditary non-polyposis colorectal cancer), diabetes (maturityonset diabetes of youth), and juvenile open-angle glaucoma. Although these genes account for a minority of affected cases, knowledge of rare genes could shed light on other, more common forms of the disease. For example, the identification of the gene for the common form of open-angle glaucoma, primary open-angle glaucoma, was made possible by prior linkage mapping of the candidate chromosomal region in families with the juvenile form of the disease, a mendelian, rarer subset with earlier age of onset. 19 
Genes of modest effect
There are examples of common disease alleles of modest effect that have been detected by linkage analysis. A case in point is APOE, a disease allele which predisposes to both a common, late-onset form of Alzheimer's disease and cardiovascular disease. 20 APOE was identified as a disease locus by linkage mapping rather than association, although the presence of association may have augmented the power to detect it. Another example is HLA, which has a role in type I diabetes. 21 Also, simulation studies have shown that oligogenic, three-or four-locus models (a genotypic relative risk of 2 and 1.7 per locus, respectively) may explain most of the genetic variance in common, non-mendelian disorders such as bipolar disorder, and that the genes involved are detectable by linkage analysis. 22 It may also be possible to enrich the sample for disease-allele carriers, thus augmenting the power to detect linkage. Enrichment strategies can employ criteria such as illness severity, clinical subtypes, age of onset, gender, and biological covariates (when available). For example, as mentioned earlier, early onset was pivotal in identifying genes for familial breast or colorectal cancer, and Alzheimer's disease. In contrast, late onset appeared to maximize linkage for a subset of prostate cancer. 23 There are, in addition, novel multilocus linkage Molecular Psychiatry methods that allow for the simultaneous consideration of susceptibility from multiple chromosomal regions. 24 Because of the presumed multilocus nature of complex diseases, conventional linkage methods that operate under the implicit or explicit assumption of a single disease gene (with the possible exception of heterogeneity between, but not within families) and treat multiple disease loci as if they were independent of each other, may not have sufficient power to detect complex disease genes, especially genes of small effect. [24] [25] [26] [27] A case in point is a recent linkage report on interaction between loci on chromosomes 2 and 15 that increases susceptibility to diabetes. 25 In the initial genome scan, linkage to chromosome 15 was unremarkable by conventional linkage analysis. However, using the interactional model, the evidence of linkage to both of these loci increased substantially. Another novel method employs neural networks which are geared to identify sets of marker loci that jointly display non-random allele sharing, or linkage. 26, 27 This method, which examines the inheritance of all markers jointly over the whole genome, may be able to exploit interactions among the multiple disease loci that underlie complex diseases. 26, 27 Methods for multipoint linkage analysis can further increase power to detect linkage. These methods enhance the ability of linkage analysis to uncover minor gene effects, though some genes of modest influence may still escape detection.
As mentioned earlier, when linkage analysis was contrasted with association-based methods, the linkage approach had limited power to detect gene effects with genotypic relative risks smaller than 4. 10 However, these results were based on the assumption of a single allele at the disease locus and markers that include this locus, an assumption favorable for the detection of linkage disequilibrium. 17 When linkage disequilibrium is not favored in this manner, the advantage of association mapping over the linkage method becomes less clear. 28 
Resources
There are two issues to consider: clinical resources (ie, sample size) and cost. It has been argued that the clinical samples required to detect linkage to genes of modest effect (relative risk of 2 or less) are generally beyond reach (thousands of subjects), and that in contrast the required sample size for association studies is vastly less than for linkage. 10 However, as mentioned earlier, other investigators [16] [17] [18] contend that the complexity of genome-wide association studies with SNPs has been underestimated. As a result, the samples required for these studies may be vastly larger than the original estimates, to the point of being beyond reach. In contrast, according to some simulations, 22 the sample size required for linkage (hundreds of affected sib-pairs; see also Conflicting results below) is well within reason. Additionally, genotyping cost can be prohibitive for association studies. For example, at an estimated cost of $1.00 per SNP, testing 100000 SNPs in 1000 subjects would amount to $100 million. And since the required sample size is likely much larger, [16] [17] [18] the actual cost may be substantially higher. In contrast, genome-wide screens of linkage samples, which generally require 300 or 600 markers (for 10 cM and 5 cM scans, respectively), can be conducted at a fraction of the cost, even if one allows for follow-up, high-density mapping of 'promising' regions (as judged by linkage signals obtained in the initial screen). Of course, new technologies for high-speed SNP testing should lower the outlay for association mapping, but a substantial disparity in cost between the basic designs for two approaches may remain.
Conflicting results
Although inconsistent results in linkage analysis of complex disease may be taken as evidence for the limited utility of this method, there are alternative explanations. In particular, there is substantial variation in research design across studies, which constrains the interpretation of results. Studies can differ greatly in ascertainment strategy and analytical methods, partly reflecting the ongoing debate concerning the optimal study design for linkage detection. 29, 30 Thus, some investigators advocate the use of multiplex extended pedigrees and model-based (or parametric) linkage analysis, whereas others opt for nuclear families with affected sib-pairs and model-free (or nonparametric) linkage methods.
There are other important issues to consider. For example, assuming oligogenic models for complex traits like bipolar disorder, 22 several hundred affected sib-pairs may be required for linkage detection. 22, 31 Samples of this magnitude, though attainable in practice, are not common in genome scans. As noted earlier, small samples are prone to statistical fluctuations and difficulty in sorting out a true-positive from a falsepositive finding. Meta-analysis of multiple data sets has been offered as a potential remedy, and effective statistical methods have been developed. 32, 33 But in the absence of a common, standardized research protocol across studies, post hoc analyses require cautious interpretation. 34 Another issue concerns marker density and degree of informativeness. The average marker spacing in most genome scans of complex disorders is 10-15 cM. This marker density is thought to be cost-effective for the detection of gene effects by linkage analysis. However, in reality not all regions of the genome are equally covered by equally informative markers, and some linkages can elude detection. For example, in our own studies, evidence for linkage of bipolar disorder to chromosome 21q22, using high marker density (intervals smaller than 2 cM), 35 was missed in a 10 cM genome scan done independently on the same pedigree set. It turned out that in the genome scan, the marker nearest to the locus which gave the strongest linkage signal in the high marker density study, was 8 cM away. It appears that this distance was large enough to prevent linkage detection in the regular genome scan. Similarly, other investigators reported that support for some previously reported linkages for bipolar disorder was obtained with marker spacing denser than previous genome scans for this disorder (6 cM vs the more common 10-12 cM). 36 Other possible reasons for discrepancies in linkage results (or the interpretation thereof) include population heterogeneity, which may lead to fortuitous sample (and thereby gene effect) variation across studies, and statistical issues such as inflated linkage results due to multiple testing and appropriate thresholds for significance in replication studies. 37 
Linkage and association
Perhaps the most efficient strategy is to search for linkage and association, thus combining the merits of both methods. For example, a genome-wide scan using linkage analysis, followed by association (linkage disequilibrium) testing of putative candidate genes in regions flagged by linkage signals. 8 Compared to genome-wide association studies, this method is less labor-intensive and not as costly-the number of linkage markers tested in the genome scan is in the hundreds (as opposed to tens, or even hundreds of thousands in the genome-wide association strategy); highdensity mapping is done subsequently, and only in the target genomic regions, in preparation for a search for the disease gene, on a molecular level. Linkage and association can be analyzed jointly. 16, 38, 39 Evidence of association and linkage may indicate which markers in a candidate region are closest to a disease locus. 36 If allelic association is present, it can augment the power of linkage analysis. 40, 41 Thus, marginal evidence for linkage or association, deemed inconclusive or inconsequential, could be enhanced by a joint analysis to unearth a bona fide gene effect. For example, a joint linkage and association test greatly increased the sensitivity of the analysis, with evidence for a major locus for psoriasis at the MHC region, on chromosome 6p21. 40 Similarly, whereas linkage analysis alone showed modest evidence for linkage between essential hypertension and putative candidate genes, a joint linkage analysis conditional on linkage disequilibrium increased the power of the analysis, yielding statistically significant results for the type I angiotensin II receptor locus. 41 The disadvantage of this method is that genes of modest effect may be missed in the genome-wide scan that precedes the more intense study of putative candidate regions.
Linkage and association analysis can also be enriched by the study of population isolates. 42 In isolated populations, there are fewer disease-susceptibility alleles and, possibly, fewer genes for a given disease than in more heterogenous populations. As reviewed, 42 genetic mapping studies of complex diseases, such as essential hypertension, multiple sclerosis, diabetes, bipolar disorder, and schizophrenia, have been carried out in isolated populations, with some evidence for linkage to putative susceptibility loci. Although none of these genome scans provided evidence for linkage disequilibrium, two candidategene studies of essential hypertension (see above) and multiple sclerosis showed a substantial increase in Table 1 Hallmarks of linkage and association studies of complex disease
Linkage Association
Tests for cosegregation of a gene marker and disease Examines the co-occurrence of a gene marker and disease phenotype within a family.
phenotype, usually at the population level.
Can use various family structures, including multiplex Compares marker frequencies in unrelated cases and extended pedigrees and nuclear families with affected sibcontrols (case-control design). Simplex families and sib-pair pairs.
families (family design) can also be used.
Can test both random, anonymous DNA markers and Usually examines candidate-gene markers. candidate-gene polymorphisms.
Geared to detect genes of moderate-to-large effect, though Geared to identify genes of modest effect. some genes of modest effect may also be detected by joint linkage and association analysis, multilocus linkage models that examine gene effects from multiple genomic regions, and enrichment of the sample for disease-allele carriers (eg, studying population isolates or searching for phenotypic subtypes with reduced genetic heterogeneity).
Genome-wide scans typically employ 300-600 markers
Usually examines a small number of 'hypothesis-driven' (corresponding to marker-to-marker intervals of 10 cM and candidate genes. However, with the advent of extensive 5 cM, respectively), with denser marker coverage in follow-SNP maps, genome-wide association studies are expected to up studies of designated candidate regions.
employ upwards of 500 000 SNPs.
Potential linkages have been reported with samples of Potential associations with select candidate genes have various sizes and configurations, such as several dozen been reported with samples ranging from several dozen to extended pedigrees or hundreds of sib-pairs. Usually, several hundred case-control pairs or family trios. Often, however, the linkage evidence is at the 'suggestive' level, however, there is a strong potential for false-positives due with limited power to discern a true-positive from a falseto ethnic stratification or the low prior odds of selecting the positive. Replications and/or substantially larger samples 'right' candidate gene in the absence of knowledge of a may be required to firm up the evidence. biological substrate. Genome-wide SNP searches include all potential candidate genes, but given the vast number of permutations there may still be a strong potential for falsepositives requiring appropriate statistical criteria. Wholegenome SNPs studies may require thousands of subjects. However, confounding factors (eg, marked allelic or population heterogeneity) may render the sample size required unattainable.
Genotyping cost is within reach given the sample size and Genotyping cost can be prohibitive given the vast number number of markers proposed for a genome scan and for of genotypes (number of subjects × number of SNPs). subsequent high-density mapping of candidate regions.
Technological advances (eg, high-speed SNP testing) could lower the cost substantially, but the linkage approach may retain a significant cost advantage.
statistical significance for the type I angiotensin II receptor gene (hypertension) and the myelin basic protein gene (multiple sclerosis), when linkage and association were analyzed jointly. Simulation studies suggest that stable isolated populations may be better suited for mapping complex disease genes than the more common, rapidly expanding population isolates (eg, Finland, Sardinia); that is, the genealogical history of the isolate may determine its usefulness for the detection of genes for complex traits. 12 Thus, as also suggested by some empirical data, 43 most isolated populations may prove no more useful for mapping of complex disease genes than large outbred populations. Still, since the linkage disequilibrium levels in these populations are somewhat more pronounced than in samples from more heterogeneous populations, 43 these populations may have increased utility for the detection of linkage disequilibrium. 14 
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Another potentially useful approach for enhancing linkage and association analysis involves the combined use of path analysis, segregation analysis, and linkage/association analysis. 44 The advantage of this method is in the systematic exploration of a large number of potential risk factors-both genetic and non-genetic, or environmental-for interaction effects. It has been suggested that, compared to the vast majority of linkage and association studies which focus primarily on a straightforward genotype-phenotype relationship, this approach may be optimal for extracting comprehensive information from family data, with implications for the discovery of complex disease genes of small effect. 44 
Conclusion
Complex diseases may require complex solutions: no one method is sufficient or optimal. Linkage mapping is the preferred method for genes of moderate-to-large effect, though some genes of modest effect can also be detected. High-density genome-wide association analysis targets the entire complement of genes (including genes of small effect) but is costly and constrained by genomic, statistical and computational complexities. A joint linkage and association analysis, including follow-up of candidate chromosomal regions, may have greater efficiency than either method considered alone. The ever-improving map of the human genome, together with multipoint analysis of closely linked marker loci, will augment the power of linkage and association studies. DNA pooling, DNA-chip technologies, high-speed SNP testing, and advanced biocomputing should expedite marker-intensive studies and improve cost-efficiency. The development of new statistical tools, such as multilocus linkage strategies that examine the risk conferred jointly by multiple genes over the whole genome, and combined models that take stock of interaction effects of genetic and non-genetic risk factors, should also aid the mapping of complex disease genes. Last but not least, the establishment of large-scale cell repositories and well-characterized clinical samples (including multiplex extended pedigrees, affected sib-pairs, simplex families and case-control data, and detailed information that may allow derivation of putative phenotypic subsets), using common, standardized procedures, will be crucial to the success of these studies.
